Roivant Sciences Ltd. $ROIV Shares Sold by Swiss National Bank

Swiss National Bank decreased its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 3.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 705,146 shares of the company's stock after selling 22,100 shares during the period. Swiss National Bank owned approximately 0.10% of Roivant Sciences worth $7,115,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of ROIV. Parallel Advisors LLC raised its holdings in Roivant Sciences by 80.5% in the 1st quarter. Parallel Advisors LLC now owns 2,485 shares of the company's stock valued at $25,000 after acquiring an additional 1,108 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in Roivant Sciences by 478.6% in the 4th quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock valued at $28,000 after acquiring an additional 1,948 shares during the last quarter. UMB Bank n.a. raised its holdings in Roivant Sciences by 112.7% in the 1st quarter. UMB Bank n.a. now owns 4,143 shares of the company's stock valued at $42,000 after acquiring an additional 2,195 shares during the last quarter. Fifth Third Bancorp raised its holdings in Roivant Sciences by 59.3% in the 1st quarter. Fifth Third Bancorp now owns 5,118 shares of the company's stock valued at $52,000 after acquiring an additional 1,905 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in Roivant Sciences by 83.0% in the 1st quarter. GAMMA Investing LLC now owns 6,493 shares of the company's stock valued at $66,000 after acquiring an additional 2,945 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company's stock.

Insider Buying and Selling

In other Roivant Sciences news, major shareholder Vivek Ramaswamy sold 577,007 shares of the stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $11.46, for a total transaction of $6,612,500.22. Following the sale, the insider directly owned 37,284,108 shares in the company, valued at $427,275,877.68. This represents a 1.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Eric Venker sold 100,000 shares of the stock in a transaction that occurred on Monday, July 21st. The stock was sold at an average price of $11.52, for a total transaction of $1,152,000.00. Following the sale, the chief executive officer owned 1,462,223 shares in the company, valued at approximately $16,844,808.96. This trade represents a 6.40% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 3,090,503 shares of company stock worth $34,991,546. 10.80% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. The Goldman Sachs Group raised shares of Roivant Sciences to a "strong-buy" rating and set a $19.00 price target for the company in a research note on Thursday, July 10th. HC Wainwright reissued a "buy" rating and issued a $18.00 price target on shares of Roivant Sciences in a research note on Wednesday, June 18th. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $16.50.

Roivant Sciences Stock Up 0.7%

Shares of Roivant Sciences stock traded up $0.0850 during mid-day trading on Friday, hitting $11.8950. The stock had a trading volume of 1,208,570 shares, compared to its average volume of 5,742,279. The firm has a 50-day moving average of $11.42 and a two-hundred day moving average of $10.91. Roivant Sciences Ltd. has a 12-month low of $8.73 and a 12-month high of $13.06. The firm has a market cap of $8.09 billion, a P/E ratio of -17.05 and a beta of 1.15.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings data on Thursday, May 29th. The company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.15). The company had revenue of $7.57 million for the quarter, compared to analysts' expectations of $62.17 million. Roivant Sciences had a negative return on equity of 15.90% and a negative net margin of 2,111.79%.During the same period in the previous year, the business posted ($0.23) EPS. Sell-side analysts expect that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.